StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NRIXBullishResearch Analysisnews
Materiality pending

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%

Jul 25, 2024, 11:02 AM EDT1 sourcesAI-analyzed

AI summary

What happened, with direct paths to the underlying reporting

NRIX shares gained 3.1% recently, closing at $21.09. Analysts estimate a mean price target of $26.42, suggesting 25.3% upside. Positive earnings estimate revisions strengthen the case for a stock surge. NRIX has a Zacks Rank #2 (Buy), indicating strong performance potential. Analyst agreement on price targets means potential for significant stock movement.

  • NRIX shares gained 3.1% recently, closing at $21.09.
  • Analysts estimate a mean price target of $26.42, suggesting 25.3% upside.
  • Positive earnings estimate revisions strengthen the case for a stock surge.
  • NRIX has a Zacks Rank #2 (Buy), indicating strong performance potential.
  • Analyst agreement on price targets means potential for significant stock movement.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.